1. Home
  2. EQ vs BTCT Comparison

EQ vs BTCT Comparison

Compare EQ & BTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EQ
  • BTCT
  • Stock Information
  • Founded
  • EQ 2017
  • BTCT 2006
  • Country
  • EQ United States
  • BTCT China
  • Employees
  • EQ N/A
  • BTCT N/A
  • Industry
  • EQ Biotechnology: Pharmaceutical Preparations
  • BTCT Other Consumer Services
  • Sector
  • EQ Health Care
  • BTCT Real Estate
  • Exchange
  • EQ Nasdaq
  • BTCT Nasdaq
  • Market Cap
  • EQ 24.8M
  • BTCT 26.2M
  • IPO Year
  • EQ 2018
  • BTCT N/A
  • Fundamental
  • Price
  • EQ $0.59
  • BTCT $4.73
  • Analyst Decision
  • EQ Buy
  • BTCT
  • Analyst Count
  • EQ 2
  • BTCT 0
  • Target Price
  • EQ $5.00
  • BTCT N/A
  • AVG Volume (30 Days)
  • EQ 117.7K
  • BTCT 974.3K
  • Earning Date
  • EQ 11-13-2024
  • BTCT 02-15-2025
  • Dividend Yield
  • EQ N/A
  • BTCT N/A
  • EPS Growth
  • EQ N/A
  • BTCT N/A
  • EPS
  • EQ N/A
  • BTCT N/A
  • Revenue
  • EQ $45,914,000.00
  • BTCT $8,482,000.00
  • Revenue This Year
  • EQ $4.76
  • BTCT $11.07
  • Revenue Next Year
  • EQ N/A
  • BTCT $5.27
  • P/E Ratio
  • EQ N/A
  • BTCT N/A
  • Revenue Growth
  • EQ 7.70
  • BTCT N/A
  • 52 Week Low
  • EQ $0.56
  • BTCT $1.32
  • 52 Week High
  • EQ $3.25
  • BTCT $26.58
  • Technical
  • Relative Strength Index (RSI)
  • EQ 31.96
  • BTCT 35.29
  • Support Level
  • EQ $0.56
  • BTCT $4.69
  • Resistance Level
  • EQ $0.67
  • BTCT $5.80
  • Average True Range (ATR)
  • EQ 0.05
  • BTCT 1.51
  • MACD
  • EQ -0.01
  • BTCT -1.17
  • Stochastic Oscillator
  • EQ 10.53
  • BTCT 4.72

About EQ Equillium Inc.

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

About BTCT BTC Digital Ltd.

BTC Digital Ltd is a crypto asset technology company based in the U.S. with a focus on bitcoin mining. The company also generates revenue through mining machine resale and rental business operations.

Share on Social Networks: